Carregant...

Single Dose of Bisphosphonate Preserves Gains in Bone Mass Following Cessation of Sclerostin Antibody in Brtl/+ Osteogenesis Imperfecta Model

Sclerostin antibody has demonstrated a bone-forming effect in pre-clinical models of osteogenesis imperfecta, where mutations in collagen or collagen-associated proteins often result in high bone fragility in pediatric patients. Cessation studies in osteoporotic patients have demonstrated that scler...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Bone
Autors principals: Perosky, Joseph E., Khoury, Basma M., Jenks, Terese N., Ward, Ferrous S., Cortright, Kai, Meyer, Bethany, Barton, David K., Sinder, Benjamin P., Marini, Joan C., Caird, Michelle S., Kozloff, Kenneth M.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5077648/
https://ncbi.nlm.nih.gov/pubmed/27641475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bone.2016.09.013
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!